OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome
Valeria Buzzelli, Emilia Carbone, Antonia Manduca, et al.
Psychopharmacology (2022) Vol. 240, Iss. 1, pp. 137-147
Closed Access | Times Cited: 15
Valeria Buzzelli, Emilia Carbone, Antonia Manduca, et al.
Psychopharmacology (2022) Vol. 240, Iss. 1, pp. 137-147
Closed Access | Times Cited: 15
Showing 15 citing articles:
Cannabidiol and positive effects on object recognition memory in an in vivo model of Fragile X Syndrome: Obligatory role of hippocampal GPR55 receptors
Antonia Manduca, Valeria Buzzelli, Alessandro Rava, et al.
Pharmacological Research (2024) Vol. 203, pp. 107176-107176
Open Access | Times Cited: 8
Antonia Manduca, Valeria Buzzelli, Alessandro Rava, et al.
Pharmacological Research (2024) Vol. 203, pp. 107176-107176
Open Access | Times Cited: 8
Psilocybin for the treatment of Alzheimer’s disease
Siyi Zheng, Rong Ma, Yang Yang, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 7
Siyi Zheng, Rong Ma, Yang Yang, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 7
The brain serotonin system in autism
A. Ya. Rodnyy, Е. М. Кондаурова, А. С. Цыбко, et al.
Reviews in the Neurosciences (2023) Vol. 35, Iss. 1, pp. 1-20
Closed Access | Times Cited: 15
A. Ya. Rodnyy, Е. М. Кондаурова, А. С. Цыбко, et al.
Reviews in the Neurosciences (2023) Vol. 35, Iss. 1, pp. 1-20
Closed Access | Times Cited: 15
Multi-level profiling of the Fmr1 KO rat unveils altered behavioral traits along with aberrant glutamatergic function
George Ntoulas, Charalampos Brakatselos, Gerasimos Nakas, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
George Ntoulas, Charalampos Brakatselos, Gerasimos Nakas, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Unraveling psilocybin’s therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression
Magdalena Kolasa, Agnieszka Nikiforuk, Agata Korlatowicz, et al.
Psychopharmacology (2024)
Open Access | Times Cited: 5
Magdalena Kolasa, Agnieszka Nikiforuk, Agata Korlatowicz, et al.
Psychopharmacology (2024)
Open Access | Times Cited: 5
Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice
Rika Takaba, Daisuke Ibi, Keisuke Yoshida, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 397, Iss. 5, pp. 3019-3035
Open Access | Times Cited: 12
Rika Takaba, Daisuke Ibi, Keisuke Yoshida, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 397, Iss. 5, pp. 3019-3035
Open Access | Times Cited: 12
Neuroplasticity of children in autism spectrum disorder
Zilin Chen, Xu Wang, Si Zhang, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 3
Zilin Chen, Xu Wang, Si Zhang, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 3
Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review
James J Gattuso, Carey Wilson, Anthony J. Hannan, et al.
Journal of Neurochemistry (2023)
Open Access | Times Cited: 8
James J Gattuso, Carey Wilson, Anthony J. Hannan, et al.
Journal of Neurochemistry (2023)
Open Access | Times Cited: 8
The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges
Mauro Scala, Chiara Fabbri, Paolo Fusar‐Poli, et al.
CNS Spectrums (2024), pp. 1-15
Closed Access | Times Cited: 2
Mauro Scala, Chiara Fabbri, Paolo Fusar‐Poli, et al.
CNS Spectrums (2024), pp. 1-15
Closed Access | Times Cited: 2
The Psychedelic N,N-Dipropyltryptamine Prevents Seizures in a Mouse Model of Fragile X Syndrome via a Mechanism that Appears Independent of Serotonin and Sigma1 Receptors
Richa Tyagi, Tanishka S. Saraf, Clinton E. Canal
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 10, pp. 1480-1491
Open Access | Times Cited: 3
Richa Tyagi, Tanishka S. Saraf, Clinton E. Canal
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 10, pp. 1480-1491
Open Access | Times Cited: 3
A perspective on psychedelic teratogenicity: the utility of zebrafish models
Omer A. Syed, Benjamin Tsang, Rotem Petranker, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 10, pp. 664-673
Closed Access | Times Cited: 3
Omer A. Syed, Benjamin Tsang, Rotem Petranker, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 10, pp. 664-673
Closed Access | Times Cited: 3
Role of peroxisome proliferator-activated receptors α and γ in mediating the beneficial effects of β-caryophyllene in a rat model of fragile X syndrome
Alessandro Rava, Valeria Buzzelli, Alessandro Feo, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 136, pp. 111234-111234
Open Access
Alessandro Rava, Valeria Buzzelli, Alessandro Feo, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 136, pp. 111234-111234
Open Access
Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses
Peter Hess
The Transmitter (2023)
Open Access
Peter Hess
The Transmitter (2023)
Open Access
Company on brink takes psilocybin to trial for fragile X syndrome
Peter Hess
The Transmitter (2023)
Closed Access
Peter Hess
The Transmitter (2023)
Closed Access
Going on Trial: Serotonin drug; psilocybin phase 2; placebo response data
Peter Hess
The Transmitter (2023)
Open Access
Peter Hess
The Transmitter (2023)
Open Access
